Skip to content

Released Nov 14, 2025, after the close

10-Q filed Nov 14, 2025, 45 days after period end · 0001493152-25-023477

Q2 2026 · 10-Q
Revenue$36.32M+92.4% vs Q2 2025−9.7% vs Q1 2026
Net Income$13.70MN/M vs Q2 2025N/M vs Q1 2026
EPS Diluted$0.01N/M vs Q2 2025N/M vs Q1 2026
Gross Profit$14,073,033+71.7%
Operating Income$8,213,746+135.7%
Operating Cash Flowderived$5,104,273+250.4%
Free Cash Flowderived$5,000,939+266.5%
Margins · derived
Gross margin38.7%−4.7 pt vs Q2 2025
Operating margin22.6%+4.2 pt vs Q2 2025
Net margin37.7%+96.2 pt vs Q2 2025

What the release said

The release

Same quarter

MetricQ2 2026Q2 2025Q2 2024Q2 2023
Revenue$36.32M$18.88M$14.16M$8.59M
Net Income$13.70M-$11.04M$14.93M$1.52M
EPS Diluted$0.01-$0.01$0.01$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR